The regulation of the urinary excretion of endothelin (U(ET)V) and its
clinical significance has not yet been established. The present study
was designed to examine the effect of angiotensin II (A-II), arginine
vasopressin (AVP), and nifedipine on U(ET)V. Anesthetized Munich-Wist
ar rats were infused with low (50 ng/kg/min) and high (500 ng/kg/min)
doses of A-II for 30 min. Both doses significantly increased U(ET)V, f
rom nondetectable (ND) levels to 155 +/- 54 (P < .03) and 450 +/- 86 f
g/min (P < .001), respectively. This effect was accompanied by a signi
ficant increase in urine flow (UV), from 6 +/- 1 to 67 +/- 12 and 89 /- 10 muL/min, and in mean arterial pressure (MAP), from 139 +/- 4 to
187 +/- 5 and 217 +/- 3 mm Hg. Infusions of A-II with its nonspecific
antagonist, saralasin, resulted in a further increase in U(ET)V to 647
+/- 126 and 782 +/- 117 fg/min (P < .002), respectively. However, inf
usion of A-II with its specific antagonist, losartan, completely block
ed its stimulatory effect on U(ET)V. Infusion of AVP, 10 or 100 mU/kg/
h, produced increases in MAP, from 134 +/- 3 to 165 +/- 7 and 203 +/-
4 mm Hg, and in UV from 6 +/- 1 to 37 +/- 6 and 97 +/- 17 muL/min, com
parable to A-II, but AVP did not have a marked effect on U(ET)V. Infus
ion of 0.1 or 1.0 mg/kg/h of nifedipine increased U(ET)V, from ND leve
ls to 84 +/- 36 and 146 +/- 40 fg/min (P < .006), respectively, despit
e a significant decrease in MAP, from 139 +/- 8 to 118 +/-3 and 107 +/
- 3 mm Hg (P <.05), respectively. Pretreatment of rats with captopril,
1 mg/kg/h, prevented the nifedipine-induced increase in U(ET)V. Our d
ata suggest that A-II is a major regulator of urinary endothelin excre
tion. The effect was independent of urinary flow or blood pressure. Th
e effect of nifedipine on U(ET)V was abolished by captopril, suggestin
g its mediation via reflex activation of the renin-angiotensin axis.